ArticleCurrent pharmaceutical biotechnology2025
Extraction, Isolation, Characterization, and Development of Phospholipids Complex Nanocarrier for Improved Solubility, Antiasthmatic, and Pharmacokinetic Potential of Curcuminoids.
Article in Current pharmaceutical biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Fermentation-Induced Changes in Phytochemical Composition and Pharmacological Activities ofDrug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurcuma longa Linn. (Zingiberaceae) is a medicinal plant with significant biological activities owing to curcuminoids (CURs). Nevertheless, its low oral bioavailability because of low water solubility, inadequate absorption, short half-life, and rapid clearance hampered its clinical applications.
objectiveThe study aimed to extract, isolate, characterize, and formulate the Phospholipon ®90H complex and evaluate for improved solubility, antiasthmatic and pharmacokinetic potential of CURs.
methodsPhospholipon®90H-based complex of curcuminoids (CPLC) was synthesized via solvent evaporation technique and reported an improvement of solubility, antiasthmatic, and pharmacokinetic potential of CURs. CPLC was physico-chemically and functionally evaluated by Fourier transforms infrared spectroscopy, differential scanning calorimetry, powder x-ray diffractometry, oral bioavailability, and antiasthmatic activity.
resultsEthyl acetate rhizome extracts (EARE) displayed ~17.42 % w/w extraction yield of CURs. CPLC revealed high entrapment of CURs (~ 92.55 % w/w) within the polar head of phospholipids. Small particle size ~ 194 nm with zeta potential value ~ -20.4 mV suggests the physical stability of CPLC. Physical analysis evidenced the formation of stable and amorphous CPLC by establishing hydrophobic and weak intermolecular forces between CURs and Phospholipon ®90H. Undoubtedly, the amorphous CPLC raised the aqueous solubility of CURs (~2-fold) compared to pure CURs. CPLC formulations (~ 20 mg/kg of CURs, p.o.) significantly lowered the leucocyte and eosinophil count compared to pure CURs. CPLC improved the oral bioavailability of CURs compared to pure CURs.
conclusionResults highlight that CPLC could be established as a breakthrough respiratory nanocarrier for CURs and other phytocompounds with respiratory potential.
Indexed as
Identifiers
39364873What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.